@xhalhunterx: Pretty pumped on this one! @Carlisle Tattoo Co. #carlisletattooco #tattootour #tattooartist #traditionaltattoo #blackandgreytattoo

Hal Hunter
Hal Hunter
Open In TikTok:
Region: AU
Thursday 27 August 2026 08:41:42 GMT
22522
1989
22
95

Music

Download

Comments

guitarsbringthepeace
GuitarsBringThePeace :
2026-08-27 21:43:08
158
therealsethers
seth :
Me last weekend 🥲
2026-08-29 07:15:34
10
micky_macleod
Micky Macleod :
it’s a dog eat dog world
2026-08-27 09:01:18
27
kannon.jones
Kannon Jones :
And some crack my guy
2026-08-28 07:16:48
32
pride_sin_alex
Alex :
this is just Ludacris from big mouth
2026-08-28 04:31:28
3
bigbillyschili
Bigbillyschili :
A NEW LEVEL 🔥
2026-08-30 04:39:35
3
cam.irish
cam.irish :
Hard
2026-09-11 18:39:31
1
thornextattoo
Tim Thorne Tattooer :
hard as nails
2026-08-28 12:55:01
4
t_grizzle72
Tucker :
2026-08-27 21:30:11
1
xcoconutx8
xcoconutx :
new video on youtube when,?????
2026-08-27 13:41:48
1
sarajane868686
Sarajane8686 :
Ooooh 🔥🔥🔥
2026-08-27 08:46:49
1
nmalone65
Nicholas Malone :
Y’all want some of that while he’s got it out?
2026-08-29 04:08:07
2
john_rockerr
Shaggy_shag :
Nice crack dawg shi I meant tat
2026-08-29 03:55:34
2
hfhhjtfa
malpal :
buttcrack
2026-08-28 04:38:35
2
huntsman1996
Waverly Saunders :
2026-08-28 03:55:49
1
To see more videos from user @xhalhunterx, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About